LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

23.54 2.71

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

23.54

Máximo

23.81

Métricas clave
By Trading Economics
Ingresos	675K 53M
Ventas	1.8M 148M
P/B Media del Sector	13.544 77.671
Margen de beneficios	35.57
Empleados	181
EBITDA	1.7M 80M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+43.95% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	223M 2.8B
Apertura anterior	20.83
Cierre anterior	23.54

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 dic 2025, 00:04 UTC

Adquisiciones, fusiones, absorciones

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

12 dic 2025, 16:42 UTC

Adquisiciones, fusiones, absorciones

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

13 dic 2025, 16:48 UTC

Adquisiciones, fusiones, absorciones

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dic 2025, 08:00 UTC

Adquisiciones, fusiones, absorciones

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dic 2025, 00:24 UTC

Adquisiciones, fusiones, absorciones

Want a Piece Of SpaceX? -- Barrons.com

12 dic 2025, 23:49 UTC

Adquisiciones, fusiones, absorciones

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dic 2025, 22:52 UTC

Charlas de Mercado

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dic 2025, 22:32 UTC

Ganancias

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 dic 2025, 20:45 UTC

Ganancias

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dic 2025, 20:41 UTC

Charlas de Mercado

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dic 2025, 20:20 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dic 2025, 19:23 UTC

Ganancias

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dic 2025, 18:35 UTC

Adquisiciones, fusiones, absorciones

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dic 2025, 18:33 UTC

Adquisiciones, fusiones, absorciones

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dic 2025, 18:31 UTC

Charlas de Mercado

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dic 2025, 17:49 UTC

Ganancias

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dic 2025, 17:34 UTC

Adquisiciones, fusiones, absorciones

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12 dic 2025, 17:33 UTC

Adquisiciones, fusiones, absorciones

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12 dic 2025, 17:33 UTC

Adquisiciones, fusiones, absorciones

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12 dic 2025, 17:32 UTC

Adquisiciones, fusiones, absorciones

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12 dic 2025, 17:31 UTC

Adquisiciones, fusiones, absorciones

Orange to Buy the Stake for EU4.25B in Cash

12 dic 2025, 17:24 UTC

Charlas de Mercado

Argentina Predicts Record Wheat Crop -- Market Talk

12 dic 2025, 17:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

12 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 dic 2025, 17:18 UTC

Charlas de Mercado

Ganancias

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12 dic 2025, 17:09 UTC

Charlas de Mercado

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12 dic 2025, 17:09 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

12 dic 2025, 16:47 UTC

Charlas de Mercado

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

12 dic 2025, 16:39 UTC

Charlas de Mercado

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

43.95% repunte

Estimación a 12 Meses

Media 34 USD 43.95%

Máximo 35 USD

Mínimo 33 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.